Spravato (Esketamine) Nasal Spray: Understanding Dosage, Administration, and Safety in India

Navigating the complexities of mental health treatments can feel overwhelming, especially when dealing with challenging forms of depression. For individuals in India seeking advanced therapeutic options, Spravato, a medication containing esketamine, offers a new avenue. This innovative treatment, administered as a nasal spray, is specifically designed for adults battling major depressive disorder with suicidal thoughts or behaviors, and treatment-resistant depression (TRD). Understanding how Spravato works, its prescribed dosages, and the safety protocols involved is paramount for patients and their caregivers.

Spravato isn't a typical daily pill. Instead, it's administered under strict medical supervision, often in a healthcare facility. This ensures that potential side effects are managed promptly and the treatment is delivered effectively. The active ingredient, esketamine, belongs to a class of drugs known as NMDA receptor blockers, which differs from traditional antidepressants and works rapidly to alleviate depressive symptoms.

What is Spravato and How Does It Work?

Spravato is a prescription-only medication whose active component is esketamine. It's formulated as a nasal spray, making its administration unique compared to oral medications. Esketamine functions by targeting the N-methyl-D-aspartate (NMDA) receptor in the brain. Unlike many older antidepressants that primarily affect serotonin or norepinephrine, esketamine's action on NMDA receptors appears to facilitate the rapid formation of new synaptic connections in brain regions affected by chronic stress and depression. This neuroplasticity is thought to be the key mechanism behind its swift antidepressant effects.

It's vital to grasp that Spravato is not a standalone cure but a part of a comprehensive treatment plan. Doctors typically prescribe it alongside an oral antidepressant to manage the underlying depressive disorder more effectively. The combination aims to provide robust relief and sustained improvement.

Spravato Dosage: Tailored to Your Needs

The dosage and administration schedule for Spravato are highly individualized and depend on the specific condition being treated. Doctors devise a plan that balances therapeutic efficacy with patient safety. The treatment typically involves two phases: an induction phase and, if necessary, a maintenance phase.

Induction Phase: The Starting Point

The induction phase is the initial period of treatment designed to establish the optimal therapeutic dose. This phase usually lasts for 4 weeks and involves more frequent administrations of Spravato. The goal here is to quickly achieve a significant reduction in depressive symptoms.

• Week 1: The induction phase often begins with a dosage of 56 mg. This might be administered as two 28 mg nasal sprays, one in each nostril.
• Subsequent Weeks (Weeks 2-4): For the following weeks, the typical dosage escalates to 84 mg, administered twice per week. This 84 mg dose is usually divided into three 28 mg nasal sprays. For example, a patient might receive one spray in each nostril, followed by an additional spray in one nostril.

Throughout the induction phase, close monitoring by a healthcare professional is essential. They will observe your response to the medication, check for any adverse effects, and ensure the treatment is progressing as planned.

Dosage Adjustments and Side Effects

It's not uncommon for individuals to experience side effects. If these become bothersome or unmanageable, your doctor may adjust the dosage. A common adjustment is to reduce the dose to 56 mg, administered twice per week. This flexibility allows the treatment to be tailored to your tolerance level while still aiming for therapeutic benefit.

Maintenance Phase: Sustaining Improvement

After the initial 4-week induction phase, your doctor will assess whether Spravato treatment should continue. This decision hinges on how well the medication has worked for your specific condition and how you've tolerated it. If Spravato has proven beneficial and is well-tolerated, you might transition to a maintenance phase.

The maintenance phase involves less frequent administration of Spravato, often once every week or even less frequently, depending on your doctor's assessment. The dosage might also be adjusted during this phase. The primary aim of the maintenance phase is to sustain the improvements achieved during the induction period and prevent relapse. This phase is not always necessary, and the duration of Spravato treatment is always determined on a case-by-case basis.

How to Administer Spravato Nasal Spray

Administering Spravato requires precision and adherence to specific instructions to ensure its effectiveness and safety. Each Spravato nasal spray device contains 28 mg of esketamine and delivers two sprays. To achieve the prescribed dose, you will typically use multiple devices.

1. Preparation: Before use, ensure the nasal spray device is prepared correctly as per your doctor's or the provided instructions. This usually involves priming the device.
2. Administration: You will spray the medication into your nostrils. It's crucial to follow the exact number of sprays and the order in which they should be administered into each nostril as directed by your healthcare provider. For instance, a 56 mg dose might involve using two devices, delivering a total of four sprays (two sprays per device, one in each nostril per device). An 84 mg dose would involve using three devices.
3. Post-Administration: After spraying, you should remain in the healthcare facility for a specified period, typically at least 2 hours, for monitoring.

It's imperative not to blow your nose or inhale forcefully immediately after administration, as this could affect the absorption of the medication.

What Strength Does Spravato Come In?

Spravato is available in a single strength of 28 milligrams (mg) per nasal spray device. However, this 28 mg unit is used to construct higher doses. For example:

• A 56 mg dose pack contains two 28 mg nasal spray devices. Using both devices provides the 56 mg total dose.
• An 84 mg dose pack contains three 28 mg nasal spray devices. Using all three devices delivers the 84 mg total dose.

Your doctor will prescribe the appropriate dose pack based on your treatment plan.

Safety and Monitoring: A Critical Component

Spravato is associated with certain risks, and therefore, its administration is strictly regulated. A significant aspect of Spravato treatment is the REMS (Risk Evaluation and Mitigation Strategy) program. This program is designed to ensure that patients understand the potential risks and benefits and that the medication is administered safely.

Key safety considerations include:

• Administration Setting: Spravato must be administered in a certified healthcare setting where a healthcare provider can monitor you.
• Post-Administration Observation: You will need to stay at the healthcare facility for at least 2 hours after receiving your dose for monitoring.
• Sedation and Dissociation: Spravato can cause sedation and dissociation, which are temporary effects that require monitoring.
• Potential for Abuse: Like other drugs that affect the brain, there is a potential for abuse, which is why strict administration protocols are in place.
• Blood Pressure Changes: Spravato can temporarily increase blood pressure, necessitating monitoring.

Patients are strongly encouraged to discuss the REMS program and any concerns they have with their doctor. Information is also available through the Spravato REMS program website or by calling their dedicated helpline.

When to Consult a Doctor

If you are considering Spravato for depression or are currently undergoing treatment, open communication with your doctor is key. You should consult your doctor immediately if you experience any of the following:

• Worsening depression or suicidal thoughts and behaviors.
• Any new or concerning physical symptoms, such as chest pain or difficulty breathing.
• Severe dizziness or confusion.
• Unusual or severe side effects.
• Questions about your dosage or treatment plan.

Remember, Spravato is a powerful tool in the management of certain severe depressive conditions, but it requires careful, professional guidance. Your healthcare team is your most important resource in navigating this treatment journey safely and effectively.

Frequently Asked Questions (FAQ)

Q1: Can Spravato be taken at home?

No, Spravato must be administered in a certified healthcare setting under the supervision of a healthcare professional. Patients must also remain at the facility for at least 2 hours post-administration for monitoring.

Q2: How long does the effect of Spravato last?

The antidepressant effects of Spravato can begin to appear relatively quickly, sometimes within hours or days of administration. However, the duration of these effects and the need for continued treatment vary significantly among individuals and depend on the phase of treatment (induction vs. maintenance).

Q3: Is Spravato addictive?

Spravato (esketamine) has a potential for abuse, which is why it is a prescription medication administered under strict medical supervision and regulated by a REMS program. It is not intended for recreational use.

Q4: What are the common side effects of Spravato?

Common side effects can include dizziness, nausea, sedation, vertigo, decreased physical activity, and anxiety. More serious side effects, though less common, can occur and require immediate medical attention.

Q5: Can I drive after taking Spravato?

No, you must not drive or operate heavy machinery until at least 2 hours after your dose, and only when you feel fully alert and safe to do so, as determined by your healthcare provider. You will need someone to accompany you home.